Header Logo

Connection

Rajagopal Ramesh to Humans

This is a "connection" page, showing publications Rajagopal Ramesh has written about Humans.
Connection Strength

1.681
  1. Interleukin-24: A Multidimensional Therapeutic for Treatment of Human Diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 May-Jun; 17(3):e70013.
    View in: PubMed
    Score: 0.056
  2. Exosomes in diagnostic and therapeutic applications of ovarian cancer. J Ovarian Res. 2024 May 25; 17(1):113.
    View in: PubMed
    Score: 0.052
  3. Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment. Cancer Lett. 2024 Jun 28; 592:216932.
    View in: PubMed
    Score: 0.052
  4. Tumor-targeted exosomes for delivery of anticancer drugs. Cancer Lett. 2023 04 01; 558:216093.
    View in: PubMed
    Score: 0.048
  5. Drug delivery approaches for HuR-targeted therapy for lung cancer. Adv Drug Deliv Rev. 2022 01; 180:114068.
    View in: PubMed
    Score: 0.044
  6. Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. Adv Drug Deliv Rev. 2021 11; 178:113918.
    View in: PubMed
    Score: 0.043
  7. Extracellular Vesicles in Oncology: from Immune Suppression to Immunotherapy. AAPS J. 2021 02 14; 23(2):30.
    View in: PubMed
    Score: 0.042
  8. Interleukin (IL)-24: Reconfiguring the Tumor Microenvironment for Eliciting Antitumor Response. Adv Exp Med Biol. 2021; 1290:99-110.
    View in: PubMed
    Score: 0.041
  9. Exosomes as drug delivery vehicle and contributor of resistance to anticancer drugs. Cancer Lett. 2020 08 28; 486:18-28.
    View in: PubMed
    Score: 0.039
  10. Progress in extracellular vesicle biology and their application in cancer medicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 07; 12(4):e1621.
    View in: PubMed
    Score: 0.039
  11. Tumor-Targeted Dendrimer Nanoparticles for Combinatorial Delivery of siRNA and Chemotherapy for Cancer Treatment. Methods Mol Biol. 2020; 2059:167-189.
    View in: PubMed
    Score: 0.038
  12. Combinatorial Nanoparticle Delivery of siRNA and Antineoplastics for Lung Cancer Treatment. Methods Mol Biol. 2019; 1974:265-290.
    View in: PubMed
    Score: 0.036
  13. A Non-invasive Liquid Biopsy Screening of Urine-Derived Exosomes for miRNAs as Biomarkers in Endometrial Cancer Patients. AAPS J. 2018 07 09; 20(5):82.
    View in: PubMed
    Score: 0.035
  14. Exosomes as Theranostics for Lung Cancer. Adv Cancer Res. 2018; 139:1-33.
    View in: PubMed
    Score: 0.033
  15. Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. Adv Cancer Res. 2018; 137:115-170.
    View in: PubMed
    Score: 0.033
  16. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine. 2018 02; 14(2):373-384.
    View in: PubMed
    Score: 0.033
  17. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Sci Rep. 2017 11 07; 7(1):14674.
    View in: PubMed
    Score: 0.033
  18. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther. 2017 08; 16(8):1470-1486.
    View in: PubMed
    Score: 0.032
  19. Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems. Drug Dev Ind Pharm. 2017 Sep; 43(9):1391-1401.
    View in: PubMed
    Score: 0.032
  20. Multifaceted Applications of Chitosan in Cancer Drug Delivery and Therapy. Mar Drugs. 2017 Mar 27; 15(4).
    View in: PubMed
    Score: 0.032
  21. Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment. Top Curr Chem (Cham). 2017 Apr; 375(2):35.
    View in: PubMed
    Score: 0.032
  22. Nanosomes carrying doxorubicin exhibit potent anticancer activity against human lung cancer cells. Sci Rep. 2016 12 12; 6:38541.
    View in: PubMed
    Score: 0.031
  23. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy. IEEE Trans Nanobioscience. 2016 12; 15(8):849-863.
    View in: PubMed
    Score: 0.031
  24. IL-24 modulates the high mobility group (HMG) A1/miR222 /AKT signaling in lung cancer cells. Oncotarget. 2016 Oct 25; 7(43):70247-70263.
    View in: PubMed
    Score: 0.031
  25. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration. J Nanobiotechnology. 2016 Jun 21; 14(1):47.
    View in: PubMed
    Score: 0.030
  26. Exploitation of Exosomes as Nanocarriers for Gene-, Chemo-, and Immune-Therapy of Cancer. J Biomed Nanotechnol. 2016 Jun; 12(6):1159-73.
    View in: PubMed
    Score: 0.030
  27. Tumor-targeted and pH-controlled delivery of doxorubicin using gold nanorods for lung cancer therapy. Int J Nanomedicine. 2015; 10:6773-88.
    View in: PubMed
    Score: 0.029
  28. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015 Dec; 22(12):581-90.
    View in: PubMed
    Score: 0.029
  29. Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget. 2015 Jun 30; 6(18):16271-86.
    View in: PubMed
    Score: 0.028
  30. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis. PLoS One. 2015; 10(3):e0122439.
    View in: PubMed
    Score: 0.028
  31. Nanoparticle-based cisplatin therapy for cancer. Ther Deliv. 2015 Feb; 6(2):115-9.
    View in: PubMed
    Score: 0.027
  32. Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Curr Gene Ther. 2015; 15(2):182-92.
    View in: PubMed
    Score: 0.027
  33. EGFR-targeted plasmonic magnetic nanoparticles suppress lung tumor growth by abrogating G2/M cell-cycle arrest and inducing DNA damage. Int J Nanomedicine. 2014; 9:3825-39.
    View in: PubMed
    Score: 0.026
  34. Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/Plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm. 2014 Aug 04; 11(8):2720-33.
    View in: PubMed
    Score: 0.026
  35. Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer. AAPS PharmSciTech. 2014 Jun; 15(3):709-21.
    View in: PubMed
    Score: 0.026
  36. EGFR-targeted hybrid plasmonic magnetic nanoparticles synergistically induce autophagy and apoptosis in non-small cell lung cancer cells. PLoS One. 2011; 6(11):e25507.
    View in: PubMed
    Score: 0.022
  37. Adenovirus-mediated interleukin (IL)-24 immunotherapy for cancer. Methods Mol Biol. 2010; 651:241-70.
    View in: PubMed
    Score: 0.019
  38. Cancer targeting using tumor suppressor genes. Front Biosci. 2008 Jan 01; 13:1959-67.
    View in: PubMed
    Score: 0.017
  39. Nanoparticle-mediated gene delivery to the lung. Methods Mol Biol. 2008; 433:301-31.
    View in: PubMed
    Score: 0.017
  40. Vitamin E succinate in combination with mda-7 results in enhanced human ovarian tumor cell killing through modulation of extrinsic and intrinsic apoptotic pathways. Cancer Lett. 2007 Sep 08; 254(2):217-26.
    View in: PubMed
    Score: 0.016
  41. Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation. Mol Cancer Ther. 2007 Apr; 6(4):1440-9.
    View in: PubMed
    Score: 0.016
  42. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer. 2007 Feb 02; 6:11.
    View in: PubMed
    Score: 0.016
  43. mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther. 2007 Feb; 15(2):287-94.
    View in: PubMed
    Score: 0.016
  44. Apoptin studies illuminate intersection between lipidomics and tumor suppressors. Mol Ther. 2007 Jan; 15(1):7-9.
    View in: PubMed
    Score: 0.016
  45. MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic. Curr Gene Ther. 2006 Feb; 6(1):73-91.
    View in: PubMed
    Score: 0.015
  46. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther. 2005 Oct; 12(4):707-15.
    View in: PubMed
    Score: 0.014
  47. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res. 2005 Apr 15; 65(8):3017-24.
    View in: PubMed
    Score: 0.014
  48. Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation-associated -7 (mda-7)/interleukin-24 (IL-24) gene. Cancer Gene Ther. 2005 Mar; 12(3):238-47.
    View in: PubMed
    Score: 0.014
  49. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb; 4(2):291-304.
    View in: PubMed
    Score: 0.014
  50. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat. 2004 Dec; 3(6):647-57.
    View in: PubMed
    Score: 0.014
  51. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol. 2004 Dec; 23(12):850-7.
    View in: PubMed
    Score: 0.014
  52. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther. 2004 Nov; 11(11):733-9.
    View in: PubMed
    Score: 0.013
  53. Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther. 2004 Apr; 9(4):510-8.
    View in: PubMed
    Score: 0.013
  54. Adenovirus-mediated PTEN treatment combined with caffeine produces a synergistic therapeutic effect in colorectal cancer cells. Cancer Gene Ther. 2003 Nov; 10(11):803-13.
    View in: PubMed
    Score: 0.013
  55. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003 Aug 15; 63(16):5105-13.
    View in: PubMed
    Score: 0.012
  56. Increased uptake of liposomal-DNA complexes by lung metastases following intravenous administration. Mol Ther. 2003 Mar; 7(3):409-18.
    View in: PubMed
    Score: 0.012
  57. RNA binding proteins (RBPs) and their role in DNA damage and radiation response in cancer. Adv Drug Deliv Rev. 2022 Dec; 191:114569.
    View in: PubMed
    Score: 0.012
  58. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene. 2002 Jul 04; 21(29):4558-66.
    View in: PubMed
    Score: 0.011
  59. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage. Int J Radiat Biol. 2021; 97(8):1109-1120.
    View in: PubMed
    Score: 0.010
  60. On the issue of transparency and reproducibility in nanomedicine. Nat Nanotechnol. 2019 07; 14(7):629-635.
    View in: PubMed
    Score: 0.009
  61. HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells. Sci Rep. 2017 08 30; 7(1):9694.
    View in: PubMed
    Score: 0.008
  62. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep. 2017 Apr; 37(4):2382-2390.
    View in: PubMed
    Score: 0.008
  63. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016 10 04; 7(40):64820-64835.
    View in: PubMed
    Score: 0.008
  64. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.
    View in: PubMed
    Score: 0.007
  65. Targeting single-walled carbon nanotubes for the treatment of breast cancer using photothermal therapy. Nanotechnology. 2013 Sep 20; 24(37):375104.
    View in: PubMed
    Score: 0.006
  66. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One. 2012; 7(4):e34833.
    View in: PubMed
    Score: 0.006
  67. Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res. 2009 Dec 01; 15(23):7299-308.
    View in: PubMed
    Score: 0.005
  68. Structural mapping of post-translational modifications in human interleukin-24: role of N-linked glycosylation and disulfide bonds in secretion and activity. J Biol Chem. 2009 Oct 30; 284(44):30526-33.
    View in: PubMed
    Score: 0.005
  69. Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther. 2008 Dec; 7(12):3842-51.
    View in: PubMed
    Score: 0.004
  70. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol. 2007 Nov; 31(5):985-1007.
    View in: PubMed
    Score: 0.004
  71. Human interleukin 24 (MDA-7/IL-24) protein kills breast cancer cells via the IL-20 receptor and is antagonized by IL-10. Cancer Immunol Immunother. 2007 Feb; 56(2):205-15.
    View in: PubMed
    Score: 0.004
  72. mda-7/IL24 kills pancreatic cancer cells by inhibition of the Wnt/PI3K signaling pathways: identification of IL-20 receptor-mediated bystander activity against pancreatic cancer. Mol Ther. 2005 May; 11(5):724-33.
    View in: PubMed
    Score: 0.003
  73. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan; 11(1):160-72.
    View in: PubMed
    Score: 0.003
  74. Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther. 2004 Dec; 10(6):1085-95.
    View in: PubMed
    Score: 0.003
  75. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004 Jun; 9(6):818-28.
    View in: PubMed
    Score: 0.003
  76. MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family. Int Immunopharmacol. 2004 May; 4(5):649-67.
    View in: PubMed
    Score: 0.003
  77. The tumor suppressor activity of MDA-7/IL-24 is mediated by intracellular protein expression in NSCLC cells. Mol Ther. 2004 Mar; 9(3):355-67.
    View in: PubMed
    Score: 0.003
  78. Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther. 2003 Oct; 5(5):463-74.
    View in: PubMed
    Score: 0.003
  79. MDA-7 negatively regulates the beta-catenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther. 2003 Aug; 8(2):207-19.
    View in: PubMed
    Score: 0.003
  80. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S23-37.
    View in: PubMed
    Score: 0.003
  81. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002 Nov; 1(13):1201-9.
    View in: PubMed
    Score: 0.003
  82. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002 Sep; 8(9):2963-9.
    View in: PubMed
    Score: 0.003
  83. PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med. 2002 Aug; 8(8):451-61.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.